PROSCA/BLADDR 2023 | Trimodal therapy for MIBC: debates and innovations in radiation oncology

Paul Sargos, MD, Institut Bergonié, Bordeaux, France, delves into crucial questions faced by radiation oncologists in proposing trimodal therapy for localized muscle-invasive bladder cancer (MIBC). He addresses the longstanding debate on treating pelvic lymph nodes during radiotherapy, citing historical studies and recent presentations, indicating a potential survival benefit from including pelvic lymph nodes. Another key consideration is optimizing treatment for microscopic disease, adapting to bladder movement and deformations. Dr Sargos highlights adaptive radiotherapy’s promising data, showcasing improved local control and safety by adjusting radiation fields to patient and bladder dynamics. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.